YE Wenjie, ZHANG Qiyan, CAO Jianfeng, YU Kexin. Effect of "Five-in-One" of traditional Chinese medicine combined with low concentration of atropine in prevention and control of myopia in adolescents[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 113-117. DOI: 10.7619/jcmp.20240416
Citation: YE Wenjie, ZHANG Qiyan, CAO Jianfeng, YU Kexin. Effect of "Five-in-One" of traditional Chinese medicine combined with low concentration of atropine in prevention and control of myopia in adolescents[J]. Journal of Clinical Medicine in Practice, 2024, 28(6): 113-117. DOI: 10.7619/jcmp.20240416

Effect of "Five-in-One" of traditional Chinese medicine combined with low concentration of atropine in prevention and control of myopia in adolescents

More Information
  • Received Date: January 22, 2024
  • Revised Date: March 01, 2024
  • Available Online: April 01, 2024
  • Objective 

    To explore the safety and effectiveness of the comprehensive therapy of "Five-in-One" of traditional Chinese medicine combined with low concentration of atropine in the prevention and control of myopia in adolescents.

    Methods 

    Eighty adolescents diagnosed with mild myopia were included in the study. According to the wishes of the subjects and their guardians, they were divided into control group with 40 cases and traditional Chinese medicine intervention group with 40 cases. The control group received 0.01% atropine sulfate eye drops in both eyes once before bedtime every night, the traditional Chinese medicine intervention group underwent twice-weekly comprehensive therapy of "Five-in-One" of traditional Chinese medicine on the basis of local application of medication in the control group. Both groups received a 12-month intervention course. Follow-up visits were conducted before intervention and at 3, 6, and 12 months after treatment. The international standard visual acuity chart was used to examine the changes in unaided distance visual acuity before and after treatment in both groups. The changes of distant visual acuity of naked eye before and after treatment were measured in two groups. The changes in equivalent spherical lens power before and after treatment in both groups were measured by mydriatic refraction combined with a computer optometer. The changes in axial length before and after treatment were measured using an optical biometer. The adverse reactions after treatment in both groups were compared.

    Results 

    In the control group, the uncorrected distance visual acuity decreased compared with that before intervention as the treatment time prolonged, while was gradually increased in the traditional Chinese medicine intervention group compared with that before intervention (P < 0.05). At 12 months after treatment, the uncorrected distance visual acuity in the traditional Chinese medicine intervention group was higher than that in the control group (P < 0.05). With the prolongation of treatment time, the equivalent spherical lens power gradually increased in both groups (P < 0.05).At 12 months after treatment, the equivalent spherical lens power in the traditional Chinese medicine intervention group was lower than that in the control group (P < 0.05). The axial length gradually increased with the prolongation of treatment time in both groups (P < 0.05). At 6 and 12 months after treatment, the axial length in the traditional Chinese medicine intervention group was shorter than that in the control group (P < 0.05). After using 0.01% atropine, 8 children in the control group developed outdoor photophobia symptoms; after treatment with the comprehensive therapy of "Five-in-One" of traditional Chinese medicine combined with 0.01% atropine sulfate eye drops in the traditional Chinese medicine intervention group, 4 children developed outdoor photophobia symptoms, but the symptoms disappeared after 2 weeks of medication.

    Conclusion 

    The comprehensive therapy of "Five-in-One" in traditional Chinese medicine combined with low-concentration atropine is significantly more effective than low-concentration atropine alone in effectively controlling the progression of refractive myopia and reducing its adverse reactions.

  • [1]
    JAKOBSEN T M, HANSEN N C, HVID-HANSEN A, et al. Myopia in children and adolescents[J]. Ugeskr Laeger, 2023, 185(48): V04230251.
    [2]
    XIANG Z Y, ZOU H D. Recent epidemiology study data of myopia[J]. J Ophthalmol, 2020, 2020: 4395278.
    [3]
    宋逸凡. 健康中国战略背景下儿童青少年近视现状调查及防控政策研究[J]. 百科论坛电子杂志, 2021, (1): 73-73. doi: 10.12253/j.issn.2096-3661.2021.01.094
    [4]
    PUGAZHENDHI S, AMBATI B, HUNTER A A. Pathogenesis and prevention of worsening axial elongation in pathological myopia[J]. Clin Ophthalmol, 2020, 14: 853-873. doi: 10.2147/OPTH.S241435
    [5]
    UPADHYAY A, BEUERMAN R W. Biological mechanisms of atropine control of myopia[J]. Eye Contact Lens Sci Clin Pract, 2020, 46(3): 129-135. doi: 10.1097/ICL.0000000000000677
    [6]
    CHAN D K, FUNG Y K, XING S X, et al. Myopia prevention, near work, and visual acuity of college students: integrating the theory of planned behavior and self-determination theory[J]. J Behav Med, 2014, 37(3): 369-380. doi: 10.1007/s10865-013-9494-9
    [7]
    宋艳霞, 杨晓格, 赵敬聪, 等. 中医耳穴贴压对3~16岁近视儿童眼调节功能的改善作用[J]. 中国临床医生杂志, 2020, 48(5): 620-622. doi: 10.3969/j.issn.2095-8552.2020.05.036
    [8]
    邹海东. 低浓度硫酸阿托品防控近视进展眼用制剂制备的专家共识(2023)[J]. 中华试验眼科杂志, 2023, 41(3): 201-205.
    [9]
    FU A C, STAPLETON F, WEI L, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression[J]. Br J Ophthalmol, 2020, 104(11): 1535-1541.
    [10]
    荣军博, 符爱存, 吕勇, 等. 0. 01%阿托品滴眼液控制学龄儿童近视发展的疗效[J]. 中华实验眼科杂志, 2020, 38(6): 494-498. doi: 10.3760/cma.j.cn115989-20200329-00223
    [11]
    HA A, KIM S J, SHIM S R, et al. Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis[J]. Ophthalmology, 2022, 129(3): 322-333. doi: 10.1016/j.ophtha.2021.10.016
    [12]
    ZHAO C L, CAI C Y, DING Q, et al. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis[J]. BMC Ophthalmol, 2020, 20(1): 478. doi: 10.1186/s12886-020-01746-w
    [13]
    CARR B J, MIHARA K, RAMACHANDRAN R, et al. Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of Alpha2A-adrenoceptors in vitro[J]. Invest Ophthalmol Vis Sci, 2018, 59(7): 2778-2791. doi: 10.1167/iovs.17-22562
    [14]
    ZOU L L, LIU R, ZHANG X H, et al. Upregulation of regulator of G-protein signaling 2 in the sclera of a form deprivation myopic animal model[J]. Mol Vis, 2014, 20: 977-987.
    [15]
    相璐, 姜思宇, 沈玺. 近视的发病机制及防控研究进展[J]. 眼科新进展, 2021, 41(5): 488-494. https://www.cnki.com.cn/Article/CJFDTOTAL-XKJZ202105020.htm
    [16]
    周丽琼, 周运波. 耳穴贴压联合眼部穴位按摩治疗儿童/青少年假性近视的临床观察[J]. 湖南中医药大学学报, 2022, 42(3): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZX202203009.htm
    [17]
    钟瑞英, 郎建英, 张曼曼, 等. 不同的推拿频率防控近视进展的临床研究[J]. 湖南中医药大学学报, 2022, 42(3): 397-400. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZX201811019.htm
    [18]
    刘小婷. 外源性bFGF联合定志丸加减对豚鼠形觉剥夺性近视巩膜重塑的研究[D]. 咸阳: 陕西中医药大学, 2017.
    [19]
    吕晖, 王丽平, 沈凤仁, 等. 腹针治疗儿童近视眼临床疗效观察[J]. 中国针灸, 2015, 35(6): 567-570. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZE201506019.htm
  • Cited by

    Periodical cited type(7)

    1. 曹贻元. 舒芬太尼对瑞芬太尼麻醉后早期疼痛的预防效果. 中国卫生标准管理. 2022(15): 109-113 .
    2. 张志强. 舒芬太尼预防瑞芬太尼麻醉后早期疼痛的临床研究. 首都食品与医药. 2019(04): 36-37 .
    3. 李玉琢. 舒芬太尼联合右美托咪定的麻醉和术后镇痛效果. 河南医学研究. 2019(09): 1634-1635 .
    4. 郑孝振,韩箫笛,宋俊杰,毛姗姗,白明松,洪道先. 鞘内注射舒芬太尼对慢性神经痛大鼠脊髓背角NMDA受体表达的影响. 中国合理用药探索. 2019(05): 1-3+7 .
    5. 买宇,张春华,鲍杰,孙坤. 羟考酮与舒芬太尼术后镇痛对结肠癌患者免疫功能的影响比较. 中国药业. 2019(21): 47-49 .
    6. 赵立,梁永新. 瑞芬太尼联合丙泊酚应用于食道异物取出术的麻醉效果分析. 医学信息. 2018(11): 93-95 .
    7. 刘毅,赖敏. 舒芬太尼对雷米芬太尼麻醉后缓解早期疼痛的临床疗效评价. 抗感染药学. 2018(12): 2139-2141 .

    Other cited types(0)

Catalog

    Article views (124) PDF downloads (9) Cited by(7)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return